Felezenexor
TīmeklisKaryopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering modern cancer therapies, and the Menarini Bunch, ("Menarini"), a privately-held, leading... TīmeklisMenarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Mil.. Berlin-Chemie AG entered into an agreement to acquire Stemline Therapeutics, …
Felezenexor
Did you know?
Tīmeklis2024. gada 21. dec. · – Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries – Karyopharm to Receive $75 Million Upfront, then Eligible to Receive Up to $202.5 … Tīmeklis2024. gada 20. maijs · Menarini actively develops Elzonris (marketed in US and Europe for BPDCN) for multiple hematologic malignancies, including AML, CMML and …
Tīmeklis2024. gada 24. dec. · Karyopharm y Menarini Group suscriben un acuerdo de licencia exclusiva para comercializar NEXPOVIO® (selinexor) en Europa y otros territorios globales clave Tīmeklis2024. gada 21. maijs · La decisión de la CE se espera en un plazo aproximado de 60 días tras la recomendación del CHMP. En diciembre de 2024, Karyopharm y Menarini Group firmaron un acuerdo de licencia exclusiva para ...
Tīmeklis2024. gada 24. dec. · Karyopharm e Menarini Group firmam acordo de licença exclusivo para comercializar o NEXPOVIO® (selinexor) na Europa e em outros importantes territórios globais TīmeklisKaryopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma PR
Tīmeklis2024. gada 22. maijs · CHMP로부터의 긍정적 소견은 판매 승인에 대한 과학적 권고이며, 유럽연합 집행위원회 (EC)가 Karyopharm의 NEXPOVIO 적용에 대한 결정을 내리기 전의 최종 단계 중 하나다. EC의 결정은 CHMP 권고 이후 약 60일 이내에 나올 전망이다. 2024년 12월 Karyopharm과 Menarini는 유럽에서 ...
Tīmeklis2024. gada 21. dec. · Menarini has a deep commitment for developing treatments addressing oncological and hematologic diseases. Menarini actively develops … candice hoshi uchealthTīmeklis2024. gada 23. dec. · /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), ein kommerzielles Pharmaunternehmen, das neuartige Krebstherapien entwickelt, und die Menarini... fish passage conference richland waTīmeklisNEWTON, Mass. and FLORENCE, Italy - Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group, a privately-held, leading... October 3, 2024 candice howell fort worthTīmeklis2024. gada 21. maijs · -- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy, May 21, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group … fish passage conference 2022 juneTīmeklis2024. gada 21. marts · Menarini actively develops Elzonris (marketed in US and Europe for BPDCN) for multiple hematologic malignancies, including AML, s CMML and … candice headTīmeklis2024. gada 21. dec. · Menarini actively develops Elzonris (marketed in US and Europe for BPDCN) for multiple hematologic malignancies, including AML, s CMML and … candice highTīmeklis2024. gada 21. dec. · December 21, 2024 - 7:30 am. NEWTON, Mass. and FLORENCE, Italy, Dec. 21, 2024-- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial … candice huett springfield mo